Bayer(US:BAYRY) Xin Hua She·2025-12-10 03:11Core Insights - China is emerging as a significant source of innovation in the global biopharmaceutical sector, showcasing strong capabilities in areas like cell and gene therapy [1] - Bayer views China as a critical market for business growth and a strategic pillar in its global innovation framework [1] Group 1: Innovation Landscape - China has transitioned from being a "follower" to an "innovation source" in the biopharmaceutical field, driven by government support for technology and industry integration, a vibrant R&D ecosystem, and strong market demand [1] - Bayer has established five R&D and innovation centers in China, including the Shanghai Co.Lab platform focused on cutting-edge fields, which has welcomed seven biotech companies [2] Group 2: Collaborative Efforts - The newly opened Open Innovation Center in Beijing will act as a local innovation accelerator, enhancing Bayer's R&D capabilities by connecting global resources [2] - Bayer collaborates with local pharmaceutical startups to expedite the global market entry of original Chinese innovations and partners with research and clinical institutions to strengthen basic science research and clinical translation [2] Group 3: Academic Partnerships - Chinese universities and research institutions play a vital role in Bayer's innovation strategy, with over 100 research projects conducted with Tsinghua University and Peking University in the past two decades [3] - Bayer's collaborations extend to various fields, including probiotics with Jiangnan University and artificial intelligence with Shanghai Jiao Tong University, highlighting the strong capability of the Chinese academic community in translating basic research into new drug development [3]